Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study.

Mitchell BD, McArdle PF, Shen H, Rampersaud E, Pollin TI, Bielak LF, Jaquish C, Douglas JA, Roy-Gagnon MH, Sack P, Naglieri R, Hines S, Horenstein RB, Chang YP, Post W, Ryan KA, Brereton NH, Pakyz RE, Sorkin J, Damcott CM, O'Connell JR, Mangano C, Corretti M, Vogel R, Herzog W, Weir MR, Peyser PA, Shuldiner AR.

Am Heart J. 2008 May;155(5):823-8. doi: 10.1016/j.ahj.2008.01.019. Epub 2008 Mar 5.

2.

Genetics and cardiovascular disease.

Acton RT, Go RC, Roseman JM.

Ethn Dis. 2004 Autumn;14(4):S2-8-16. Review.

PMID:
15724791
3.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

4.

Aspirin in coronary artery disease: an appraisal of functions and limitations.

Würtz M.

Dan Med J. 2015 Apr;62(4):B5011. Review.

PMID:
25872543
5.

Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.

Winkelmann BR, März W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J; LURIC Study Group (LUdwigshafen RIsk and Cardiovascular Health).

Pharmacogenomics. 2001 Feb;2(1 Suppl 1):S1-73. Review.

PMID:
11258203
6.

The prognostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation.

Dretzke J, Riley RD, Lordkipanidzé M, Jowett S, O'Donnell J, Ensor J, Moloney E, Price M, Raichand S, Hodgkinson J, Bayliss S, Fitzmaurice D, Moore D.

Health Technol Assess. 2015 May;19(37):1-366. doi: 10.3310/hta19370. Review.

Supplemental Content

Support Center